Reneo Pharmaceuticals, Inc.

RPHM

US75974E1038

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
1.71 ^USD	+2.40%		+1.79%	+6.88%

Mar. 28	Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 25	North American Morning Briefing : Tech in Focus on -2-	DJ

Reneo Pharmaceuticals, Inc. authorizes a Buyback Plan.

October 29, 2023

The Board of Directors of Reneo Pharmaceuticals, Inc. has authorized a buyback plan on October 30, 2023.

Latest news about Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Concentra Biosciences, LLC submitted a non-binding proposal to acquire Reneo Pharmaceuticals, Inc. for $60 million.	Dec. 25	CI
North American Morning Briefing : Stock Futures -2-	Dec. 18	DJ
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) added to NASDAQ Biotechnology Index	Dec. 18	CI
Ladenburg Thalmann Downgrades Reneo Pharmaceuticals to Neutral From Buy	Dec. 15	MT
HC Wainwright Downgrades Reneo Pharmaceuticals to Neutral From Buy, Cuts Price Target to $1.50 From $30	Dec. 15	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 14	MT
Top Midday Decliners	Dec. 14	MT
Piper Sandler Downgrades Reneo Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $4 From $25	Dec. 14	MT
Sector Update: Health Care Stocks Ease Thursday Afternoon	Dec. 14	MT
Reneo Pharmaceuticals Says Pivotal Study of Mavodelpar Fails to Meet Primary, Secondary Endpoints; Shares Plunge	Dec. 14	MT
Baird Downgrades Reneo Pharmaceuticals to Neutral From Outperform, Cuts Price Target to $3 From $28	Dec. 14	MT
William Blair Starts Reneo Pharmaceuticals With Outperform Rating	Nov. 15	MT
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Reneo Pharmaceuticals, Inc. announces an Equity Buyback for 576,443 shares, for $4.4 million.	23-10-30	CI
Reneo Pharmaceuticals, Inc. authorizes a Buyback Plan.	23-10-29	CI
Reneo Pharmaceuticals Reports Last Patient Last Visit in Study of Mavodelpar in Primary Mitochondrial Myopathies	23-10-09	MT
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) added to S&P Global BMI Index	23-09-18	CI
Top Premarket Decliners	23-08-28	MT
Top Premarket Decliners	23-08-24	MT
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Certain Options of Reneo Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 2-AUG-2023.	23-08-01	CI
Certain Restricted stock units of Reneo Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 2-AUG-2023.	23-08-01	CI
Certain Common Stock of Reneo Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 2-AUG-2023.	23-08-01	CI

Chart Reneo Pharmaceuticals, Inc.

Duration

Period

More charts

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.67 USD

Average target price

1.9 USD

Spread / Average Target

+13.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RENEO PHARMACEUTICALS, INC.	+6.88%	55.81M
IQVIA HOLDINGS INC.	+0.67%	42.19B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.2B
MEDPACE HOLDINGS, INC.	+29.96%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.76B
UNITED THERAPEUTICS CORPORATION	+16.03%	10.4B
BIO-TECHNE CORPORATION	-4.80%	9.94B

Other Biotechnology & Medical Research